Steve E. Coutre

Learn More
At sites of vascular injury, thrombin interacts with multiple procoagulant substrates, to mediate both fibrin clotting and platelet aggregation. But upon binding to thrombomodulin on the vascular endothelium, thrombin instead activates protein C, thereby functioning as an anticoagulant and attenuating clot formation. Upon infusion in vivo, both the(More)
Idelalisib (GS-1101, CAL-101), an oral inhibitor of phosphatidylinositol 3-kinase-δ, was evaluated in a phase I study in 64 patients with relapsed indolent non-Hodgkin lymphoma (iNHL). Patients had a median (range) age of 64 (32-91) years, 34 (53%) had bulky disease (≥1 lymph nodes ≥5 cm), and 37 (58%) had refractory disease. Patients had received a median(More)
Key Points • This clinical study assessed idelalisib, a selective PI3Kd inhibitor, in 64 patients with relapsed, indolent non-Hodgkin lymphoma. • Idelalisib treatment rapidly induced durable disease responses in heavily pretreated patients with a favorable safety profile. Idelalisib (GS-1101, CAL-101), an oral inhibitor of phosphatidylinositol 3-kinase-d,(More)
  • 1